Clinical trials
Immunotherapy clinical trials
Below are recruiting immunotherapy clinical trials, each written for real people, not researchers. We’re tracking 774 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06627595Recruiting
Exercise and immunotherapy side effects in melanoma
This study looks at whether physical activity can help reduce side effects from immunotherapy in people with melanoma. You may join if you are starting a certain type of immunotherapy for melanoma.
MontpellierAges 18 years+ - NCT07632365RecruitingPhase 1/Phase 2
Immunotherapy plus chemoradiation for inoperable stage III lung cancer
This trial tests a new combination of immunotherapy and chemotherapy before and after standard chemoradiation for patients with stage III lung cancer that cannot be surgically removed. The goal is to see if this approach improves outcomes compared to chemoradiation alone.
Shanghai, XuhuiAges 18 years+ - NCT06096844RecruitingPhase 3
Chemo plus immunotherapy vs immunotherapy alone for older adults with advanced lung cancer
This trial compares chemotherapy combined with immunotherapy to immunotherapy alone for adults 70 and older with advanced non-small cell lung cancer that has a specific protein level (PD-L1 1-49%). It aims to find which treatment works better for this group.
Fayetteville, ArkansasAges 70 years+ - NCT03198546RecruitingPhase 1
CAR T therapy for advanced liver cancer with GPC3
This Phase 1 study tests a personalized immune-cell treatment (CAR T cells) for advanced liver cancer that has the GPC3 protein. It aims to see whether these engineered cells can find and kill cancer cells safely and help shrink the cancer.
Guangzhou, GuangdongAges 18–75 - NCT04821843RecruitingPhase 3
Study before-surgery treatments for esophageal cancer
This Phase 3 trial compares different “treatments before surgery” for people with esophageal (or esophagus-to-stomach) cancer. It aims to see which approach works better to control the cancer and improve outcomes after surgery.
BeijingAges 18 years+ - NCT04821778RecruitingPhase 3
Testing chemoradiotherapy for esophageal and stomach junction cancer
This Phase 3 study tests a cancer treatment plan that combines chemotherapy and radiation for people with esophageal or esophagus-stomach junction cancer. It aims to see whether this approach works better than standard care for cancers at stages I to IVA.
Anyang, HenanAges 18 years+ - NCT04957511Recruiting
Testing gut bacteria in gynecologic cancer patients on immunotherapy
This study looks at how gut bacteria may relate to how well immunotherapy works in people with advanced or returning gynecologic cancer. You may be asked to give stool samples several times so researchers can measure changes in your gut microbiome.
Orlando, FloridaAges 18 years+ - NCT05202314Recruiting
Camrelizumab plus chemo after stent for left bowel cancer
This study tests whether adding camrelizumab (an immune therapy) to chemotherapy—after a stent is placed to open a blocked left-sided colon—improves outcomes. It’s meant for people whose cancer can still be removed with surgery after the blockage is treated.
Beijing, Beijing MunicipalityAges 18–80 - NCT05229614RecruitingPhase 2
Immunotherapy plus carbon ion radiation for stable solid tumors
This trial studies whether adding carbon ion radiation to ongoing immunotherapy can help people whose cancer is currently stable. It targets solid cancers where scans show the disease is not growing quickly, aiming to improve control without causing unsafe side effects.
DarmstadtAges 18 years+ - NCT05255302RecruitingPhase 2/Phase 3
Shorter immune maintenance for stage IV lung cancer after initial treatment
This trial tests whether giving immune therapy maintenance for a shorter time helps people with stage IV non-small cell lung cancer (NSCLC) who are doing well after initial chemo-immunotherapy. It aims to keep the cancer controlled while possibly reducing treatment exposure and side effects.
Aix-en-ProvenceAges 18–74 - NCT05328024Recruiting
Testing who benefits from anti–PD-1 immunotherapy in head cancer
This study looks for signs in your tumor that can predict how well anti–PD-1 immunotherapy will work for certain head and neck cancers. You may benefit by helping doctors match the right treatment to the right patients.
Strasbourg, FranceAges 18 years+ - NCT05475613RecruitingPhase 2
Immunotherapy to shrink advanced liver cancer before transplant
This trial tests an immunotherapy “downstaging” plan to shrink hepatocellular carcinoma (a type of liver cancer) so it may become treatable with a liver transplant. You may be eligible if your cancer is beyond transplant limits but is still only in the liver, and you meet specific liver function and health requirements.
Guangzhou, GuangdongAges 18–75 - NCT05527795Recruiting
Study features that predict benefit from extra immunotherapy in melanoma
This study looks for lab and tumor features that may help predict who benefits from follow-up (adjuvant) immunotherapy after surgery for melanoma. Your past treatment and tumor samples may be used to improve future treatment decisions.
Pierre-BéniteAges 18 years+ - NCT05667857Recruiting
Tracking brain, mood, and quality of life after immunotherapy
This study follows people who have had advanced cancer and are now stable after immunotherapy, to see how thinking, mood, and daily life change over time. Some participants may also do an integrative brain-training program if they have memory or thinking problems.
Brussels, Brussels CapitalAges 18 years+ - NCT06020430Recruiting
Skipping routine radiation for advanced lung cancer after immunotherapy and chemo
This trial tests whether it is safe to skip routine radiation to the tumor bed in patients with stage III lung cancer that has responded well to immunotherapy and chemotherapy. It aims to reduce side effects while still controlling the cancer.
Wuhan, HubeiAges 18–75 - NCT06032052RecruitingPhase 2
Chemo plus immunotherapy for older adults with metastatic lung cancer
This trial tests a combination of chemotherapy and immunotherapy for people 65 or older with metastatic non-small cell lung cancer that has not been treated before and expresses PD-L1. It aims to see if this treatment can help control the cancer.
Wuhan, HubeiAges 65 years+ - NCT06035328Recruiting
Comparing different maintenance doses for wheat allergy oral immunotherapy
This study tests whether taking a maintenance dose of wheat oral immunotherapy once or twice a week is more effective for children with wheat allergy. It aims to find the best schedule to keep them protected from allergic reactions.
Bangkoknoi, BangkokAges 5–18 - NCT06114225RecruitingPhase 2
Immunotherapy and radiation before lung surgery for osteosarcoma
This trial tests a combination of immunotherapy and targeted radiation before surgery for osteosarcoma that has spread to the lungs. It aims to see if this approach can help shrink or control the lung tumors and make surgery more effective.
Shanghai, Shanghai MunicipalityAges 10–65 - NCT06218901Recruiting
Psychological distress in lung cancer patients
This study looks at how lung cancer patients experience emotional distress like anxiety or depression. It aims to better understand these feelings and how they affect patients so that support can be improved.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06229041RecruitingPhase 3
Chemo and radiation with or without immunotherapy for high-risk rectal cancer
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
BeijingAges 18–75 - NCT06256146Recruiting
Treating food allergies with modified oral immunotherapy
This study tests a new approach to oral immunotherapy for food allergies, aiming to make it safer and more effective. It's for people who have had a clear allergic reaction to a food and have a positive allergy test.
Montreal, QuebecAges 2–40 - NCT06328504Recruiting
Cashew allergy treatment with cashew protein
This trial tests whether giving very small amounts of cashew protein (like a food immunotherapy) can help children and teens with cashew allergy become less allergic. If it works, it might lower the risk of severe reactions.
Warsaw, Masovian VoivodeshipAges 4–17 - NCT06356584RecruitingPhase 2
A drug combination with or without radiation for advanced colorectal cancer
This trial tests a new drug combo (fruquintinib and sintilimab) with or without radiation for people with colorectal cancer that has spread to the liver and has not responded to earlier treatments.
Jinan, ShandongAges 18–75 - NCT06366490RecruitingPhase 1
Personalized vaccine for recurrent ovarian cancer
This trial tests a personalized cancer vaccine made from your own tumor cells. It is for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has returned after at least one round of platinum chemotherapy.
Duarte, CaliforniaAges 18 years+
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunotherapy?
- Yes. Clin2 currently lists 774 recruiting immunotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.